

ONE HUNDRED NINTH LEGISLATURE - FIRST SESSION - 2025
COMMITTEE STATEMENT (CORRECTED)
LB72

Hearing Date: Wednesday January 22, 2025
Committee On: Judiciary
Introducer: Hallstrom
One Liner: Change provisions relating to controlled substance schedules under the Uniform Controlled Substances Act

Roll Call Vote - Final Committee Action:
Advanced to General File

Vote Results:

Aye:	7	Senators Bosn, DeBoer, Hallstrom, Holdcroft, Rountree, Storer, Storm
Nay:	1	Senator McKinney
Absent:		
Present Not Voting:		

Testimony:

Proponents:

Senator Bob Hallstrom
Haley Pertzborn

Representing:

Opening Presenter
Nebraska Pharmacists Association

Opponents:

Representing:

Neutral:

Representing:

* ADA Accommodation Written Testimony

Summary of purpose and/or changes:

LB 72 would amend the Uniform Controlled Substances Act to align it with the federal Controlled Substances Act. The bill also adds xylazine, a veterinary tranquilizer that illegal drug manufacturers have added to drugs like fentanyl, as a Schedule III controlled substance.

The Uniform Controlled Substances Act regulates the manufacturing, distribution, and possession of controlled substances. It classifies controlled substances into different schedules (I, II, III, IV, or V) based on their potential for abuse, risk of harm, and medical use. Schedule I controlled substances have no accepted medical use and the highest potential for abuse. They are the most regulated and have no allowable use. Schedule I controlled substances include heroin and psychedelic drugs such as psilocybin, MDMA, and LSD. Schedule II, III, IV, and V controlled substances have legitimate medical uses but still pose a risk for abuse. Schedule II controlled substances can be used with a prescription, and Schedule III, IV, and V drugs can be used under a medical order or prescription.

Section 1: Amends § 28-405 to add and remove substances from the controlled substance schedules.



- Schedule I: Adds several synthetic opioids, stimulants, and the hallucinogenic eutylone to align with the federal act and clarifies that the inclusion of the hallucinogenic substance psilocybin in Schedule I does not prohibit the use of any pharmaceutical form of the underlying chemical compound that is FDA-approved.
- Schedule II: No change.
- Schedule III: Adds xylazine to Schedule III and provides for its use by veterinarians.
- Schedule IV: Adds zuranalone (a new FDA-approved drug for postpartum depression) and removes fenfluramine (used to treat seizures) to align with the federal act. It also allows for the conditional sale of FDA-approved medications based on psilocybin.
- Schedule V: No change.

Section 2: Amends § 28-416 to make harmonizing changes.

Section 3: Repealer.

Carolyn Bosn, Chairperson

